News
-
-
PRESS RELEASE
Jaguar Health Reports Approval of All Proposals at March 2025 Special Meeting of Stockholders
Jaguar Health announces voting results of Special Meeting of Stockholders and expect first results in Q2 2025 for crofelemer trials in rare diseases. FDA meeting anticipated for Phase 3 OnTarget trial in breast cancer patients -
-
PRESS RELEASE
Jaguar Health Adopts Limited Duration Stockholder Rights Plan to Ensure Stockholders Can Realize Long-Term Value
Jaguar Health, Inc. announces results of crofelemer trials for rare diseases and adoption of Rights Plan to deter open-market accumulation. FDA meeting expected in Q2 2025 for breast cancer study results -
-
PRESS RELEASE
Jaguar Receives Regulatory Clearance in Germany and Italy for Crofelemer for Rare Disease Study - Short Bowel Syndrome with Intestinal Failure (SBS-IF)
Jaguar Health, Inc. announces initiation of clinical trial for crofelemer in rare diseases SBS-IF and MVID. First proof-of-concept results expected in H1 2025 -
-
PRESS RELEASE
Jaguar Health Extends Collaboration for Possible Tropical Disease Priority Review Voucher and Cholera Indication for NP-300
Jaguar Health and Napo Pharmaceuticals extend collaboration with Streeterville related to development of NP-300 drug product candidate for cholera patients, aiming for Tropical Disease Priority Review Voucher from FDA -
-
PRESS RELEASE
Jaguar Health Presenting February 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts
Jaguar Health, Inc. founder Lisa Conte to present virtually at Emerging Growth Conference on Feb 18, 2025. Company focuses on sustainable pharmaceuticals derived from rainforest plants for gastrointestinal distress
